ÖZET

Amaç:

Osteopeni ve osteoporoz hemoglobinopatili hastalarda önemli bir morbidite nedenidir. Bu çalışmanın amacı talasemi majör, talasemi intermedya ve orak hücreli anemi hastalarında demir birikimi, D vitamini ve kemik mineral yoğunluğu (KMY) arasındaki ilişkiyi araştırmaktır.

Gereç ve Yöntem:

Hemoglobinopatili 102 hastadan serum örnekleri toplandı ve ferritin ve D vitamini düzeyleri ile çift enerjili X-ışını absorpsiyometrisiyle (DEXA) ölçülen KMY arasındaki ilişki araştırıldı.

Bulgular:

DEXA femoral T-skoruna göre normal KMY olan talasemi intermedya, talasemi majör ve orak hücreli anemi hasta oranı sırasıyla %56,25, %35 ve %39 idi. DEXA lomber T-skoruna göre normal KMY olan talasemi intermedya, talasemi majör ve orak hücreli anemi hasta oranı sırasıyla %31,25, %7,5 ve %41,25 idi. Hastaların ferritin değerleri ve DEXA skorları karşılaştırıldığında, femur T-skoru, lomber T-skoru, femur Z-skoru ve lomber Z-skoru, ferritin değeri yüksek olanlarda istatistiksel olarak anlamlı derecede düşüktü (p değerleri sırasıyla: 0,0005, 0,0002, <0,0001, 0,0002). Femur T-skoru, lomber T-skoru, femur Z-skoru ve lomber Z-skoru normal ve düşük D vitamini seviyesine sahip hastalarda karşılaştırıldığında, ciddi eksikliği olan hastalarda istatistiksel olarak anlamlı bir değişiklik gözlendi (p değerleri sırasıyla: 0,001, 0,001, 0,0027, 0,0003).

Sonuç:

Hemoglobinopatili hastalar DEXA ile erken yaşta taranmalıdır. Uygun D vitamini replasmanının sağlanması ve ferritin seviyelerinin normal aralığa getirilmesi çabaları osteoporoz ile ilişkili morbiditeyi azaltmada etkili olabilir.

References

Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with b thalassemia major. Bone 2011;48:425-32.

Tyler PA, Madani G, Chaudhuri R, Wilson LF, Dick EA. Theradiological appearances of thalassaemia. Clin Radiol 2006;61:40-52.

Dundar U, Kupesiz A, Ozdem S, Gilgil E, Tuncer T, Yesilipek A, et al. Bone metabolism and mineral density in patients with beta-thalassemia major. Saudi Med J 2007;28:1425-9.

Gaudio A, Morabito N, Xourafa A, Macrì I, Meo A, Morgante S, et al. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Invest 2008;31:181-4.

Vogiatzi MG, Autio KA, Schneider R, Giardina PJ. Low bone mass in prepubertal children with thalassemia major: insights in to the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab 2004;17:1415-21.

Lorincz C, Manske SL, Zernicke R. Bone health: part 1, nutrition. Sports Health 2009;1:253-60.

Balogh E, Paragh G, Jeney V. Influence of Iron on Bone Homeostasis. Pharmaceuticals (Basel) 2018;11.

Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N, et al. Thalassemia-associated osteoporosis: asystematic review on treatmentandbrief overview of the disease. Osteoporos Int 2016;27:3409-25.

Hamdy M, Salama N, Maher G, Elrefaee A. Vitamin D and Nonskeletal Complications among Egyptian Sickle Cell Disease Patients. Adv Hematol 2018;2018:3867283.

Nakamura K, Ueno K, Nishiwaki T, Okuda Y, Saito T, Tsuchiya Y, et al. Nutrition, mild hyperparathyroidism, and bone mineral density in youngJapanesewomen. Am J Clin Nutr 2005;82:1127-33.

Vupputuri MR, Goswami R, Gupta N, Ray D, Tandon N, Kumar N. Prevalence and functional significance of 25-hydroxyvitamin D deficiency and vitamin D receptorgene polymorphisms in Asian Indians. Am J Clin Nutr 2006;83:1411-9.

Pirinççioğlu AG, Akpolat V, Köksal O, Haspolat K, Söker M. Bone mineral density in children with beta-thalassemia major in Diyarbakir. Bone 2011;49:819-23.

Frisk P, Arvidson J, Ljunggren O, Gustafsson J. Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D. Bone Marrow Transplant 2012;47:657-62.

Miller RG, Segal JB, Ashar BH, Leung S, Ahmed S, Siddique S, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol 2006;81:236-41.

Bielinski BK, Darbyshire P, Mathers L, Boivin CM, Shaw NJ. Bone density in the Asian thalassaemic population: a cross-sectional review. Acta Paediatr 2001;90:1262-6.

Wonke B. Bone disease in beta-thalassaemia major. Br J Haematol 1998;103:897-901.

Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11 Suppl3:975-7.

Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults withb-thalassaemia major and intermedia. Br J Haematol 2000;111:902-7.

Dandona P, Menon RK, Houlder S, Thomas M, Hoffbrand AV, Flynn DM. Serum 1,25 dihydroxyvitamin D andosteocalcinconcentrations in thalassaemia major. Arch Dis Child 1987;62:474-7.

Inati A, Noureldine MA, Mansour A, Abbas HA. Endocrineand bone complications in b- thalassemia intermedia: current understanding and treatment. Biomed Res Int 2015;2015:813098.

Sadat-Ali M, Sultan O, Al-Turki H, Alelq A. Does high serum iron level induce low bone mass in sickle cell anemia? Biometals 2011;24:19-22.

Eren E, Yilmaz N. Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassaemia major. Int J Clin Pract 2005;59:46-51.

Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol (Oxf) 2003;58:273-9.

Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, DiFede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006;38:888-92.

Bisbocci D, Livorno P, Modina P, Gambino M, Damiano P, Cantoni R, et al. [Osteodystrophy in thalassemia major]. Ann Ital Med Int 1993;8:224-6.

Adewoye AH, Chen TC, Ma Q, McMahon L, Mathieu J, Malabanan A, et al. Sickle cell bone disease: response to vitamin D and calcium. Am J Hematol 2008;83:271-4.

Soe HH, Abas AB, Than NN, Ni H, Singh J, Said AR, et al. Vitamin D supplementation for sickle cell disease. Cochrane Database Syst Rev 2017;1:CD010858.

Sadat-Ali M, Al-Elq A, Al-Turki H, Sultan O, Al-Ali A, AlMulhim F. Vitamin D levelamongpatients with sickle cell anemia and its influence on bone mass. Am J Hematol 2011;86:506-7.

Rovner AJ, Stallings VA, Kawchak DA, Schall JI, Ohene-Frempong K, Zemel BS. High risk of vitamin D deficiency in children with sickle cell disease. J Am Diet Assoc 2008;108:1512-6.

Rosen CJ. Clinicalpractice. Vitamin D insufficiency. N Engl J Med 2011;364:248-54.

Glass LM, Su GL. Metabolic Bone Disease in Primary Biliary Cirrhosis. Gastroenterol Clin North Am 2016;45:333-43.

Ebert EC, Nagar M, Hagspiel KD. Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol 2010;8:483-9;quiz e70.

Soliman A, Adel A, Wagdy M, Al Ali M, El Mulla N. Calcium homeostasis in 40 adolescents with b-thalassemia major: A case-control study of the effects of intramuscular injection of a megadose of cholecalciferol. Pediatr Endocrinol Rev 2008;6(Suppl 1):149-154.

Singh K, Kumar R, Shukla A, Phadke SR, Agarwal S. Status of 25-hydroxyvitamin D deficiency and effect of vitamin D receptor gene polymorphisms on bone mineral density in thalassemia patients of North India. Hematology 2012;17:291-6.

Tzoulis P, Ang AL, Shah FT, Berovic M, Prescott E, Jones R, et al. Prevalence of low bone massand vitamin D deficiency in b-thalassemia major. Hemoglobin 2014;38:173-8.

Talasemi Majör, İntermedya ve Orak Hücreli Hastalarda Demir Birikimi ve D Vitamini Eksikliği ile Kemik Mineral Yoğunluğu İlişkisi

ÖZET

References